Literature DB >> 18562424

Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.

W W van den Broek1, P G H Mulder, E van Os, T K Birkenhäger, E Pluijms, J A Bruijn.   

Abstract

With respect to the pharmacological characteristic, venlafaxine is comparable with tricyclic antidepressants (TCAs), and venlafaxine might be comparable in efficacy. We performed a systematic review investigating the relative efficacy and tolerability of venlafaxine compared with TCAs (imipramine, clomipramine, amitriptyline, nortriptyline and desipramine). Relevant double-blind randomised trials were identified from systematic searches of electronic databases. An exact analysis of the estimated odds ratios of response of the TCA relative to venlafaxine showed no overall significance of treatment effect (P = 0.38). The odds ratios were not homogenous across studies (P = 0.0213). The average dose of venlafaxine was 103.5 mg/day and for the TCA 106.1 mg/day. An exact analysis of the estimated odds ratios of the withdrawals and side effects in the trials with a TCA relative to venlafaxine showed no overall significance of withdrawal. From our review, no significant difference in treatment effect between low dose of both venlafaxine and the TCAs could be found. In our opinion, because of the heterogeneity of the odds ratios, one cannot conclude that they are of equal efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562424     DOI: 10.1177/0269881108089821

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  2 in total

1.  Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.

Authors:  Iosief Abraha; Antonio Cherubini; Francesco Cozzolino; Rita De Florio; Maria Laura Luchetta; Joseph M Rimland; Ilenia Folletti; Mauro Marchesi; Antonella Germani; Massimiliano Orso; Paolo Eusebi; Alessandro Montedori
Journal:  BMJ       Date:  2015-05-27

2.  Nortriptyline, a tricyclic antidepressant, inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells.

Authors:  Sung Eun Shin; Hongliang Li; Han Sol Kim; Hye Won Kim; Mi Seon Seo; Kwon-Soo Ha; Eun-Taek Han; Seok-Ho Hong; Amy L Firth; Il-Whan Choi; Young Min Bae; Won Sun Park
Journal:  Korean J Physiol Pharmacol       Date:  2017-02-21       Impact factor: 2.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.